技術介紹 - 科技面對面

領域	展覽	技術單位	技術名稱	詳細介紹	單項預約	多項預約	收藏

多項預約送出

技術名稱	短鏈核酸藥物生產平台(治療肺纖維化核酸藥物) Platform for Oligonucleotide Drug Production (Nucleic Acid Drugs for the Treatment of Pulmonary Fibrosis)
技術單位	生物技術開發中心 Development Center for Biotechnology
隸屬部門
團隊名稱
技術 Slogan	建立自主核酸藥物研發技術，開發治療肺纖維化市場首見藥物 Establishing domestic Nucleic Acid Drug Research Technology, Developing the First-Ever Drug for Treating Pulmonary Fibrosis in the Market
技術簡介與應用	建立國內首座短鏈核酸藥物的研發製造平台，平台技術包含核酸藥物序列設計、核酸合成、分離純化與分析鑑定，可生產百毫克醫藥級純度達90%以上的核酸藥物，與台大醫學院藥理所楊鎧鍵老師共同開發治療肺纖維化的短鏈核酸藥物，在小鼠動物試驗已證實具有降低肺纖維化的功效。 Establishing the first domestic research and manufacturing platform for oligonucleotide drugs, the platform encompasses technologies such as sequence design, synthesis, purification, and analysis. It is capable of producing 100 mg pharmaceutical-grade nucleic acid drugs with a purity of over 90%. In collaboration with Dr. Yang, Kai-Chien from National Taiwan University College of Medicine, the platform has developed the first-class oligonucleotide drug for the prevention of pulmonary fibrosis. Its effectiveness in slowing down the progression of pulmonary fibrosis has been demonstrated in mouse animal trials.
技術特點	1. 建立國內首座核酸藥物研發平台 2. 百毫克醫藥級核酸藥物 3. 開發預防肺纖維化市場首見新藥 1. First platform for oligonucleotide drug development 2. Producing 100mg pharmaceutical-grade nucleic acid drugs 3. oligonucleotide drug for the prevention of pulmonary fibrosis
YOUTUBE	觀看影片
相關照片

技術名稱	智慧射頻熱消融系統 (iRFA) Intelligent Radiofrequency Ablation System (iRFA)
技術單位	工業技術研究院 Industrial Technology Research Institute
隸屬部門	生醫所
團隊名稱
技術 Slogan	全球首創整合微創手術、超音波影像的高階醫材系統 the world’s first all-in-one ultrasound imaging-guided RFA system
技術簡介與應用	工研院研發的智慧射頻熱消融系統iRFA，是全球第一個整合微創手術、超音波影像的高階醫材系統。以系統內建之影像導引功能將電極針穿刺到治療標的，進行局部熱消融治療，可應用於人體肝、肺、胰、甲狀腺結節等腫瘤，甚至腦科、心血管疾病或疼痛治療。 ITRI’s iRFA is the world’s first all-in-one ultrasound imaging-guided RFA system that features the integration of percutaneous RFA surgery and ultrasound imaging. The system has a built-in image guidance function that guides the electrode needle to the target to carry out localized ablation treatment. This technology can be applied to solid tumors in the liver, lungs, pancreas, thyroid nodules, cerebral and cardiovascular diseases. It can also be used in pain control.
技術特點	・可調式電極針，方便醫師調整消融大小、方向，精準消融。・射頻主機提供消融能量量化數據即時監控，達成完整消融。・超音波影像導引，能顯示入針即時影像和安全入針範圍讓手術更安全、精準。 Adjustable RF electrode makes it easier for doctors to adjust the ablation volume and direction for the precise ablation The RF generator provides real-time, objective monitoring to achieve complete ablation. Ultrasound image guidance displays both real-time imaging of needle insertion and the tracks for safe insertion.
YOUTUBE	觀看影片
相關照片

技術名稱	細胞生產自動化系統 Automatic Cell Production System
技術單位	工業技術研究院 Industrial Technology Research Institute
隸屬部門	生醫所
團隊名稱
技術 Slogan	細胞生產自動化且製程客製化搭配各模組應用 Automated cell production and customized process with various module applications
技術簡介與應用	工研院針對細胞治療應用需求，開發細胞智能化生產系統，使細胞生產自動化，降低勞力與不良率的成本，封閉的製造設備，也降低細胞汙染的風險。此系統為第一套包含細胞培養、品質檢測及收穫繼代等功能完整之系統，並可依據細胞生產製程客製化搭配各模組應用。 Current technology used to cultivate cells is costly, and it is impossible to obtain sufficient quantities of high-quality cells quickly. ITRI's Automatic cell production system is able to produce large quantities of cells with stable quality in five steps. The technology offers real-time monitoring of the cell growth environment, cell numbers, cell type, and detection of any contamination of the environment. Also, the entire process features an automated solution exchange procedure, which reduces the chances of contamination of the sterile environment by workers. Labor costs can be reduced by 50%.
技術特點	・可同時處理36組T75、T150、Hyper Flasks等不同細胞培養容器之傳送與定位取放作業・自動化細胞收穫繼代流程，Robot取代換液、收穫及繼代培養等人工作業・具備細胞計數、微生物污染偵測功能、細胞檢測影像自動存檔與查詢功能 Automatic CO2 regulated cell incubator: Simultaneously transporting and positioning 36 groups of T75 flask/T150 flask/HYPER flask AI cell imaging: Cell counting, contamination. Programmed Cell medium exchange. Automatic cell subculture and harvesting
YOUTUBE	觀看影片
相關照片

技術名稱	ITRI-501, 抗TIGIT抗體新藥用於實體腫瘤治療 ITRI-501, an Anti-TIGIT Monoclonal Antibody for Solid Tumor Therapy
技術單位	工業技術研究院 Industrial Technology Research Institute
隸屬部門	生醫所
團隊名稱
技術 Slogan	一種能削弱腫瘤生長的免疫活化生物製劑 An immune-activating biologic that diminished the tumor growth
技術簡介與應用	工研院利用抗體工程技術，開發「ITRI-501－抗TIGIT抗體新藥」，能夠有效阻斷TIGIT與腫瘤上的蛋白質結合，進而活化T細胞的能力。相較於現行臨床生物相似藥，ITRI-501能使毒殺癌細胞的效果提升數倍以上，且可單一治療或搭配其他藥物進行合併治療。 Based on antibody engineering technology, ITRI developed ITRI-501, an anti-TIGIT antibody drug for effectively blocking the interaction of TIGIT with cognate ligand, CD155 expressed on tumor cell, and then activated the cytotoxic T cells. Compared with the clinical drugs, ITRI-501 exhibited a superior efficacy on tumor cell killing by more than several times. It can be used as a single treatment or combined with other drugs for combinational therapy
技術特點	・能有效阻斷CD155與TIGIT結合，並較競爭者的抗TIGIT抗體具更優越激活T細胞能力。・不具免疫原性，辨認TIGIT獨特的胺基酸位置，具專利申請要件。・對表現TIGIT之調節T細胞株較競爭者(BMS與Roche)之抗TIGIT抗體具更高的細胞毒殺(ADCC)活性。・鼠源代理抗體, 2F1-LE6, 於CT26與MC38結腸癌細胞同源(syngeneic)鼠腫瘤模式證實單一用藥即具優越的療效。・於人類TIGIT基因敲入鼠同源腫瘤治療模式中，單一療法即具高度抑制MC38結腸癌細胞生長能力。・ITRI-501 can effectively block the binding of TIGIT with CD155 and has a superior capability to activate T cells than other anti-TIGIT antibodies. ・ITRI-501 is non-immunogenic and recognize an unite epitope of TIGIT, these features confer ITRI-501 patentability. ・ITRI-501 possesses a stronger antibody-dependent cell-mediated cytotoxicity (ADCC) against TIGIT-expressing regulatory T cell lines than other anti-TIGIT antibodies developed by competitors (BMS and Roche). ・2F1-LE6, a surrogate antibody of ITRI-501, has shown to have a superior curative effect in a syngeneic mouse colon tumor model (CT26 or MC38) ・In the human TIGIT gene knock-in mouse, monotherapy of ITRI-501 exhibited a promising activity in inhibiting the growth of MC38 colon cancer cells.
YOUTUBE	觀看影片
相關照片